by Combat Cancer | Jun 18, 2025 | News
Statistically, men are nearly four times more likely to be diagnosed with bladder cancer than women. But why is this? In the UK alone, bladder cancer is the seventh most common cancer in men, but only ranks seventeenth in women. This discrepancy has long been...
by Combat Cancer | Jun 7, 2025 | News
Clinical hyperthermia is defined as the therapeutic use of temperature between 41°C to 44°C. While the idea of using heat in medicine isn’t new, what makes clinical hyperthermia especially potent in the treatment of NMIBC is the way in which it enhances the...
by Combat Cancer | May 31, 2025 | News
Combat Medical is proud to announce that our Phase 3 clinical trial of HIVEC®-HEAT for patients with BCG-unresponsive non-muscle-invasive bladder cancer, has received ethical and MHRA (Medicines and Healthcare products Regulatory) approval. HIVEC®-HEAT has also been...
by Combat Cancer | May 24, 2025 | News
New Game-Changing, UK-Based Technological Innovation: The miONCO-Dx Cancer Test An inexpensive blood test that can identify the presence of 12 of the most common and lethal cancers – including cancer of the bladder and bowel – at an early stage, with over 99% accuracy...
by Combat Cancer | May 17, 2025 | News
Did you know that long-term use of urinary catheters increases the risk of bladder cancer, especially in those aged 45-60? Bladder cancer is one of the most commonly diagnosed cancers of the urinary system, and while smoking remains a major risk factor, new evidence...
by Combat Cancer | May 10, 2025 | News
While smoking remains the leading preventable risk factor for bladder cancer, and indeed most cancers, a lesser-known but significant contributor is workplace exposure to carcinogenic chemicals. In the UK, Cancer Research UK (CRUK) estimates that approximately 6% of...
Recent Comments